Automated Antimicrobial Susceptibility Testing Market to Set Phenomenal Growth and Forecast 2018-2026

Automated antimicrobial susceptibility testing products are of two types, consumables and instruments. Consumables used in automated antimicrobial susceptibility testing includes culture & growth media, ready-to-use reagents, complete reagent kits, susceptibility disks, susceptibility plates, and susceptibility cards, among others. Key players offer reagent kits and disposables, which are designed for use with their automated AST instruments, which optimizes workflow and overall laboratory efficiency. Automated microbial identification and antimicrobial susceptibility testing (AST) instruments offer rapid, accurate, and efficient susceptibility testing, thereby enhancing workflow, reducing hands-on time, and enabling rapid reporting. Automated laboratory AST instruments are equipped with Laboratory Information System (LIS) compatible software to enable better compatibility.

For Sample Copy of this Report @

Increasing prevalence of antibiotic resistance worldwide is expected to boost the automated antimicrobial susceptibility testing market growth. According to the World Health Organization’s Global Antimicrobial Surveillance System (GLASS) report of January 2018, antibiotic resistance is found among 500,000 people with suspected bacterial infections across 22 countries. The most commonly reported resistant bacteria were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae, followed by Salmonella sp.

However, the major restraining factor affecting growth of the automated antimicrobial susceptibility testing market is the product recalls of instruments for failures or for various other reasons. For instance, in 2016, bioMérieux S.A.’s VITEK 2 Gram Positive Susceptibility Test Cards were recalled by the Food and Drug Administration (FDA), as the product could lead to false susceptible results of Staphylococcus spp., Enterococcus spp., and S. agalactiae. This product was terminated in May 2017.

Key players are engaged in launching susceptibility testing systems in the market, in order to expand its product portfolio. For instance, in March 2016, Thermo Fisher Scientific launched antimicrobial susceptibility testing for Tedizolid, enabling microbiology laboratories to perform Tedizolid susceptibility testing of fastidious and non-fastidious Gram positive organisms, which cause acute bacterial skin and skin structure infections (ABSSSIs) in adults. Increasing launch of such AST testing could result in increasing adoption of susceptibility plates during the forecast period.

Moreover, in 2017, bioMérieux launched ETEST Ceftolozane/Tazobactam and ETEST Ceftazidime/Avibactam, which determines the minimum inhibitory concentration (MIC) values necessary to effectively treat infections caused by multidrug resistant organisms.

Browse 38 Market Data Tables and 25 Figures spread through 200 Pages and in-depth TOC on “Automated Antimicrobial Susceptibility Testing Market, By Product Type (Consumables and Instruments), By Detection Method (Turbidimetric and Colorimetric), By Application (Antibacterial (Tuberculosis and Sepsis), Antifungal, Anti-parasitic, and Anti-viral), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals, and Pathology/Diagnostic Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”

For More Information On This Report, Please Visit @

Rising funding for research of antibiotic resistant microbes is expected to boost the automated antimicrobial susceptibility testing market revenue over the forecast period. For instance, in November 2017, Symcel AB, a company engaged in cell-based assay tool for real-time cell metabolism measurements, secured US$ 4.23 million Horizon 2020 funding to support the company’s evaluation of improved combination testing of antibiotics against extensively drug-resistant bacteria in sepsis patients.

Respiratory Heaters Market to Perceive Substantial Growth and Forecast 2018-2026

Respiratory heaters are external heaters used with a nebulizer system. Nebulizer is a drug delivery device which allows inhalation of the drug directly into the lungs. Respiratory heaters provides the heated breathing gas and heated aerosol to the patients who required the respiratory support through nasal cannulae and tracheal tube. Respiratory heaters has the ability of mixing the oxygen and warm ambient air to users.

The high flow therapy is a type of respiratory support method which provides the high flow of medical gas through nasal cannulae. The respiratory heater warms the solution in the nebulizer and heats the diluted air. Respiratory heaters are used by patients who require the high flow therapy. These are used for treatment of asthma, chronic obstructive pulmonary disease, and bronchitis.

Ask for the Sample of the Study:

An increase in prevalence and incidence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) is a major factor that is expected to augment growth of respiratory heaters market. The Global Burden of Disease Study gives the prevalence of 251 million cases of COPD in 2016 and the bronchial asthma has approximately 358.2 million cases in 2015. The market is also driven by factors such as growing geriatric population, high prevalence of smoking, increasing pollution level. COPD is a progressive life threatening lung disease which is not curable but can be controlled by respiratory heaters. COPD is an under-diagnosed, life threatening lung disease that may progressively lead to death.

On the other hand, high cost of devices and undefined reimbursement policies in rural areas are factors restraining the market growth. For instance, on 12 December 2017, Teleflex Incorporated, a leading global provider of medical technologies, announced that its respiratory division has signed a new group purchasing agreement with Health Trust. The agreement covers Teleflex’s full line of active humidification, non-invasive ventilation (NIV), and high flow nasal cannula therapy (HFNCT) products.

In 2017, GGM’s high flow oxygen system, HUMIDOFLO HF-2900, received an award at the Taiwan Excellence Awards. Humidoflo provides more patient friendly and effective treatment for both pediatric and adult patients. GGM’s HF2900D Humidoflo represents the new state of art technology for delivery of high standard high flow therapy for pediatric and adult patients. The high flow delivery of oxygen or humidity can increase the tracheal temperature and humidity. Compared to other conventional mask type oxygen therapies, HUMIDOFLO delivers high flows of blended oxygen through unique nasal cannula.

For More Information On This Report, Please Visit @

Key players operating in the market include Teleflex Ink. , Care Fusion Corporation, Armstrong Medical, Healthcare Trust and Mediline industries, Great Group Medical., Co., Ltd, and GE Healthcare

Infant Incubator Market Emerging Growth, Trends and Forecast 2018-2026

Infant incubator is a device used for pre-matured infants, which are born before 37 weeks of pregnancy period. These pre-termed infants undergo several complications as their body temperature is low, i.e., they cannot regulate the temperature of their body when born hence, have a high risk with respect to external environment, various infections, and breathing problems that can lead to death. Incubators protect premature infants by providing them the required environment. They are small box-like structures that contain small bed and an attached trolley. These boxes are generally made of glass except the top is covered by rigid plastic.

Increasing number of premature infants is expected to boost the global infant incubator market growth over the forecast period. For instance, according to World Health Organization’s (WHO) report, 2018, around 15 million infants are born in a pre-mature state worldwide annually. The report also states that prematurity is one of the major contributors of infant mortality rate worldwide. The rate of babies born in a pre-mature state ranges from 5% – 8% in 184 countries.

Receive Sample on Infant Incubator Research:

Increasing number of studies are focused on advancements in infant incubator, which is expected to support the global infant incubator market growth over the forecast period. For instance, in March 2019, a group of researchers from Northwestern University and the Robert H. Lurie Children’s Hospital of Chicago developed wireless sensors and biosensors for monitoring vital signs with regards to contact of mother and child in replacement of wires that are used in incubator. According to the researchers, skin-to-skin contact between mother and child decreases the risk of pulmonary complications and liver infections. Implementation of such technologies in products available in the market is expected to support global infant incubator market growth over the forecast period.

High cost of infant incubator is expected to hinder the global infant incubator market growth over the forecast period. Manufacturers in the market are focused on offering technologically advanced (such as pressure diffusing mattresses and disposable skin probes) products in the market. This factor further adds to the final prices of these products. For instance, incubator may cost anywhere between US$ 600 to US$ 6,500 (GE Healthcare’s incubator costs around US$ 6,210). This factor may restrain the global infant incubator market growth in developing countries in regions such as Africa, Asia Pacific, and Latin America.

For More Information On This Report, Please Visit @

Some of the major players operating in global infant incubator market include, GE Healthcare, Atom Medical Corporation, Natus Medical Incorporated, Bistos Co. Ltd., Drägerwerk AG & Co. KGaA, UTAH Medical Products Inc., and Inspiration Healthcare Group plc.

CRISPR and CAS Gene Market Cost Structure Analysis, Growth and Forecast 2018-2026

Many food and agricultural organizations are working on receiving license for using CRISPR and CAS gene technology for creating novel products in food and agriculture business. For instance, in September 2016, agrochemical and agricultural biotechnology corporation Monsanto secured a worldwide non-exclusive license agreement for agricultural applications of CRISPR technology from the Broad Institute. CRISPR and CAS genes are also used in treating a number of diseases such as cancer, blood disorders, AIDS, and genetic disorders such as cystic fibrosis, Huntington’s etc.

Increasing prevalence of genetic disorders such as Down’s syndrome, sickle cell anaemia, and Huntington’s disease worldwide is highly contributing to the market growth of CRISPR and CAS gene market, as many genetic disabilities can be corrected using this gene editing technology. According to National Health Service (NHS) U.K. 2018 report, the highest rate of Huntington’s disease in the United Kingdom is 12 per 100,000 people. Also, in the U.S., an estimated 10 per 100,000 have the faulty Huntington’s gene and live either waiting for symptoms to begin or live/struggle with the disease.

For Sample Copy of this Report @

However, the CRISPR and CAS gene market growth is hindered by the ethical issues, which is the major concern for every gene therapy. For instance, in April 2015, the US National Institutes of Health issued a statement indicating that it will not fund any research that uses genome editing tools such as CRISPR in human embryos due to ethical issues.

Manufacturers in the CRISPR and CAS gene are collaborating with many companies for sponsoring clinical trials. Editas Medicine has licensed CRISPR and other gene editing patent rights from the Broad Institute, the Massachusetts Institute of Technology (MIT), Harvard University, and others. In March 2017, Editas reportedly entered into an agreement with Irish pharmaceutical company Allergan under, which Editas was to receive a US$ 90 million up-front payment for an option to license up to five preclinical programs targeting eye disease.

Moreover, various organizations are also focusing on new clinical trials for the CRISPR and CAS gene for cancer treatment. In 2018, CRISPR Therapeutics and Vertex launched the first in-human clinical trial of CRISPR genome editing technology sponsored by U.S. companies. The trial is testing an experimental therapy for the blood disorder β-thalassemia in Regensburg, Germany.

Increasing research and studies regarding the CRISPR and CAS gene technology is majorly driving the growth of CRISPR and CAS gene market. In 2017, Editas partnered with Juno Therapeutics for cancer-related research using CRISPR. Under the terms of the agreement, Juno had to pay Editas an initial payment of US$ 25 million, in which up to US$ 22 million will be used in research support for three programs over five years. Editas has also engaged in a three-year research and development (R&D) collaboration deal with San Raffaele Telethon Institute for Gene Therapy to research and develop next generation stem cell and T-cell therapies for the treatment of rare diseases.

For More Information On This Report, Please Visit @

Key players operating in the global CRISPR and CAS Gene market include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.


Osteoarthritis Drugs Market Industry Growth Opportunities and Forecast 2018-2026

Increasing prevalence of osteoarthritis is a major factor driving the osteoarthritis drugs market growth. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2013, total prevalence of combined symptomatic and radiographic osteoarthritis of knee and hip was around 3.8% worldwide, with 20.3 % in males and 4.5% in females.

Furthermore, key players in the market are focused on research and development of medication for symptomatic treatment of osteoarthritis, which is expected to drive the market growth. For instance, in April 2018, Flexion Therapeutics, Inc. initiated Phase III study of FX006 32 mg indicated for knee osteoarthritis. The study in expected to be completed by June 2020.

Request to Sample Report @

However, use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. In June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain.

Key players in the market are focused on research and development of new therapies in order to address the critical unmet needs of patients. For instance, in December 2017, Regeneron Pharmaceuticals initiated phase III study of Fasinumab indicated in osteoarthritis. The study is expected to be completed in May 2019.

Moreover, increasing focus of market players to launch products for symptomatic treatment of osteoarthritis is also expected to boost the market growth. For instance, in January 2019, Bioventus launched DUROLANE in distribution partnership with Athrotech in Malaysia. DUROLANE is an injection for joint fluid osteoarthritis, which is indicated in mild to moderate knee osteoarthritis.

Increasing geriatric population associated with osteoarthritis is expected to drive the market growth. According to National Center for Biotechnology Information (NCBI) report published in August 2017, knee osteoarthritis accounts for around 80% of the total disease burden and affects around 19% of adults aged 45 years and above in the U.S..

Key players in the market are focused on adopting strategies such as mergers and acquisitions to expand their product portfolio. For instance, in January 2016, Allergan acquired Anterios, Inc., a manufacturer of botulinum toxin-based prescription products.

For More Information On This Report, Please Visit @

Major players operating in the global osteoarthritis drugs market include Pfizer Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Pharma plc., Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Inc., Sanofi, Flexion Therapeutics, Inc., Regeneron, and GlaxoSmithKline Plc.


Infertility Devices Market Emerging Growth, Outlook Status and Forecast 2018-2026

Increasing infertility rates is highly contributing to the global demand for infertility devices. According to the Centres for Disease Control and Prevention (CDC) report of 2018, about 6% of women aged 15 to 44 years in the U.S. are unable to conceive after one year of trying (infertility). Also, about 12% of women aged 15 to 44 years in the U.S. have difficulty in conceiving or carrying a pregnancy to term. Infertility also affects men. According to the same source, almost 9% of men aged 25 to 44 years in the U.S. reported that they required medical help for reproduction.

Request Sample Copy of Research @

Infertility devices’ market revenue is expanding, owing to increasing (FDA) approvals for new Over-The-Counter (OTC) devices which can help individuals to conceive children. For instance, in 2014, Rinovum Women’s Health LLC announced that U.S. FDA approved its product The Stork OTC, the only home-use conception assistance device in the market for over-the-counter sales. The Stork OTC is a new option for men and women who face challenges in conceiving a child. It is an easy-to-use, drug-free, and cost-effective way to take control and optimize the chances to conceive at home.

Furthermore, advancements in technology and new product launches by various companies are highly contributing to growth of the infertility devices market. For instance, in February 2019, Merck Group launched two devices, namely Geri and Gavi, as well as Gems (a media to improve IVF), a complete culture medium suite in India to help treating infertility. These devices were developed in partnership with Genea Biomedx, for IVF treatments.

Several organizations are focused on creating a total division exclusive for treatment of infertility which consists of many devices, media, and software to assist with fertility treatment. For instance, in 2016, EMD Serono, the biopharmaceutical business of Merck KGaA, Germany, announced the development of a dedicated Fertility Technologies division that will advance the company’s leadership in fertility innovation in the U.S. and Canada. The first device launched in Fertility Technologies division was Gidget in 2017, in partnership with Genea Biomedx, Australia.

Various companies are engaged in acquiring other players in the market to strengthen their product portfolio and gain a fair share in the infertility device market. For instance, in 2018, Cooper Companies, Inc. announced that their subsidiary Cooper Surgical acquired the assets of The LifeGlobal Group and its affiliates of in-vitro fertilization (IVF) devices. This acquisition of LifeGlobal strengthened CooperSurgical’s fertility media offering thus, improving its fertility business.

Browse Full Report:

Key players operating in the global infertility devices market include Cook Group Incorporated, Esco Micro Pte. Ltd., Genea Limited, Hamilton Throne, Ltd., IHmedical A/S, Irvine Scientific (Jx Holdings Group), IVFTech Aps, Kitazato Corporation, Medgyn Products, Inc., Rocket Medical Plc., Somatex Medical Technologies GmbH, The Baker Company, Inc., The Cooper Companies, Inc., Thermo Fisher Scientific Inc., Vitrolife Ab, and Zeiss Group.

Endotracheal Tube Market to See Incredible Growth and Forecast 2018-2026

Apart from manufacturers, research organizations are also involved in research and are focusing on improvising the current endotracheal tubes to avoid problems such as growth of bacteria and fungi on the tube, appropriate placement of the tube and others, associated with their use. For instance, University of Washington, in collaboration with National Heart, Lung, and Blood Institute (NHLBI) conducted clinical trials (study completed in 2016) of endotracheal tubes with different designs to check their use in preventing ventilator acquired pneumonia. During ventilation fluids leak from mouth and throat into lungs, which can cause pneumonia. These factors are expected to support endotracheal tube market growth over the forecast period.

Get a Request Sample of Research Report @

High success rate of endotracheal tubes is expected to have a positive impact on global endotracheal tube market growth over the forecast period. For instance, according to NCBI, out of 1838 cases studied, 38 met the inclusion criteria for pre-hospital tracheal intubation during the period 2006-2016. The overall success rate of tracheal intubation was found to be 0.96 (median value). Also, apart from ventilation in traumatic conditions, endotracheal intubation is also useful in post-surgery care, such as after lung cancer surgery endotracheal intubation is used to provide artificial respiration to the patient.

Increasing product launches by manufacturers is expected to boost growth of global endotracheal tube market. For instance, BRIO DEVICE, LLC, is developing an articulate stylet to be used with endotracheal tube. Brio’s INT Navigator Articulating Stylet, which entered production in January 2019, enables the users to articulate the stylet (a device/probe used for establishing airway in tracheal intubation) tip via a thumb guided control present on handle and ultimately achieving better placement of the endotracheal tube in the trachea. Increasing focus of key players in developing products associated with the use of endotracheal tube is expected to boost the global endotracheal tube market over the forecast period.

Key players are constantly involved in business expansion to diversify their product portfolio in the market. For instance, in December 2016, Sanovas Inc., a company involved in medical intervention technology, announced the launch of its wholly owned subsidiary, Intubation Science, Inc. and LightSpeed Intubation System (LSI). LightSpeed intubation system provides a new approach for endotracheal intubation, making the procedure fast, safe, and easy.

For More Information On This Report, Please Visit @

Some of the major players operating in the global endotracheal tube market include, NA Medical LLC, Bactiguard, Kimberly-Clark, Medtronic Plc, Smiths Medical, Teleflex Inc., ConvaTec Inc., Neurovision Medical Products, Intersurgical Inc., Royax and Sanovas Inc.

Primary Biliary Cholangitis Treatment Market Set for Rapid Growth and Forecast 2018-2026

Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years. It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4 known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and environmental factors.

Get a PDF Sample of Research Report @

Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by the U.S. FDA.

Moreover, in February 2018, U.S.FDA granted orphan drug designation (ODD) to Calliditas Therapeutics AB, specialty pharmaceutical company engaged in development of high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in Stockholm, Sweden, for the treatment of Primary biliary cholangitis (PBC).

Furthermore, key players are engaged in conducting clinical trial to develop treatment for primary biliary cholangitis. For instance, in February 2017, Zydus Cadila received the US Food and Drug Administration (USFDA) approval to initiate a Phase-2 clinical trial of Saroglitazar Magnesium (Mg) in patients with Primary Biliary Cholangitis of the liver.

Manufacturers are engaged in developing therapeutic treatment for the patients with primary biliary cholangitis, which in turn is expected to drive the primary biliary cholangitis treatment market size. For instance, in March 2015, NGM Biopharmaceuticals, Inc., announced the positive results for phase 2 trial of NGM282 in patients with Primary Biliary Cirrhosis (PBC). NGM282 is an engineered protein variant of human hormone, fibroblast growth factor 19 (FGF19) that maintains bile acid and metabolic regulatory activities as well as eliminates tumorigenic effects of FGF-19. According to the study results, NGM282 is proven to be a potent regulator of bile acid synthesis.

However, lack of awareness among the patients, families and physicians, which result into delayed diagnosis for rare diseases, may hinder primary biliary cholangitis treatment market growth. Most of symptoms associated with rare diseases are masked by the symptoms of common illness and may not be detected by doctors.

Key players operating in the primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, Retrophin, Inc., Calliditas Therapeutics AB., and GlaxoSmithKline (GSK) pharmaceutical.

Medical Commode Market latest Report with Forecast 2018-2026

Medical commodes, also known as toilet chairs, are important medical equipment, designed to allow people who are bedridden, disabled, or physically challenged to safely and conveniently go to the bathroom. Bedsides this toilets can be used completely independently or with negligible help. They are found in private homes, rehabilitation centers, and hospitals, and serve a multitude of people with varying mobility needs.

Get a PDF Sample of Research Report @

Increasing number of people suffering from continence and incontinence to control their bladder and/or bowels, and person with struggle in the distance between the bed and the toilet mostly prefer bedside commode. Various reasons that someone might struggle with the distance between the bed and the bathroom, include surgical recovery and rehabilitation, urinary tract infections, balance issues, age, difficulty walking, and some medications.

Increasing prevalence of such conditions is expected to drive growth of the medical commode market. Also, growing number of surgical procedures leading to adoption of the medical commode is expected to drive growth of medical commode market. For instance, according to the National Chronic Kidney Disease 2017 Factsheet, estimated by Centers for Disease Control and Prevention (CDC), around 15% or 30 million geriatric population in the U.S. are reported to have chronic kidney disease (CKD), out of which around 48% people are suffering from severely impaired kidney function.

Moreover, key players in the market are engaged in developing medical commode, which can offers increased convenience and ease of use. For instance, Cortech Healthcare; an Isle of Man based company focused on advancing the usability, functionality, and effectiveness of independent living products offers the electric shower chain commode, which significantly increased functionality as compared to products currently available.

Request for Customization of Research Report:

Patients spend an average of two to five days in the hospital following bariatric surgery, or longer if complications develop. Patients who undergo laparoscopic bariatric surgery usually have a shorter hospital stay. Moreover, during the hospital stay and during the home recovery, heathcare professionals recommends patient to use medical commode for personal hygiene.

The two most important considerations when purchasing a bariatric commode are the dimensions and weight limit. Patients weighing more than 500 pounds should consider a bariatric commode such as the Drive Medical Deluxe Bariatric Commode, which can support weight up to 650 pounds. Furthermore, to offer the most of comfort and convenience to patient, key players in the market are offering mobile bariatric commodes.

Key players operating in the medical commode market include Medline Industries, Inc., Cardinal Health, Inc., McKesson Medical-Surgical Inc., Drive Medical, Invacare Corporation, NOVA Medical Products, Cascade Healthcare Solutions, MEYRA GmbH, Avacare medical, and Lagooni B.V.

Electrosurgery Accessories Market Regional Outlook Study and Forecast 2018-2026

Electrosurgery Accessories are the additional products used in electrosurgical procedures. Electrosurgery is the application of a high-frequency alternating polarity radio wave, this high-frequency waves are used to cut, coagulate, desiccate, or fulgurate biological tissues. The electrosurgery accessories are used in different types of procedures such as gynecological, urological, neurological, and cosmetic surgeries. Pencils, specialty electrodes, return electrodes, suction coagulators, forceps, cords, and adapters are the most commonly used electrosurgery accessories.

Get a PDF Sample of Research Report @

The electrosurgery accessories market revenue is expected to rise, owing to increasing number of new product launches with latest technology. For instance, in 2018, Olympus Corporation launched dualknife J endoscopic submucosal dissection (ESD), an electrosurgical knife, which integrates submucosal injection to support efficient, safe, and more reliable ESD performance in short procedure time.

Furthermore, the electrosurgery accessories market size is also increasing due to rising demand for ambulatory surgeries by patients, as ambulatory surgeries involve electrosurgery associated with less pain, less blood loss, minimum scarring, and reduced hospital stay. According to Healthcare Cost and Utilization Project (HCUP) 2014 report, around 11.4 million outpatient surgeries were performed in the U.S. in 2014.

The major restraining factor for electrosurgery accessories market growth is risk of accidents and fire cases due to inadequate knowledge about handling electrosurgery accessories such as specialty electrodes, return electrodes, and suction coagulators. According to the National Center for Biotechnology Information (NCBI) 2016 report, around 57% of surgeons lack adequate knowledge and awareness in managing the equipment in Ireland.

Request for Customization of Research Report:

Europe is expected to hold dominant position in the electrosurgery accessories market over the forecast period, owing to the presence of major competitors with new innovative products such as Medtronic PLC, B. Braun Melsungen AG, KLS Martin GmbH & Co. Kg, and Bowa-Electronic GmbH & Co. Kg.

Asia Pacific electrosurgery accessories market size is expected to witness significant growth in future, owing to new product launches in the region for ease of electrosurgical procedures. For instance, in 2018, Integra Lifesciences Holdings Corporation announced the launch of its new CUSA clarity ultrasonic tissue ablation platform in Japan. It is made in combination with ISOCOOL Bipolar Forceps, which as integral part of the product.

Download PDF Brochure @

Key players operating in the global electrosurgery accessories market include Medtronic PLC, Olympus Corporation, Conmed Corporation, B. Braun Melsungen AG, Bovie Medical Corporation, Ethicon, Inc. (subsidiary of Johnson & Johnson), Erbe Elektromedizin GmbH, Applied Medical Resources Corporation, Integra Lifesciences Holdings Corporation, KLS Martin Group, Megadyne Medical Products, Inc., and Bowa-Electronic GmbH & Co. Kg.